Key points are not available for this paper at this time.
The molecular cloning of the cDNA and gene encoding the renal cell carcinoma (RCC)-associated protein G250 is described. This protein is one of the best markers for clear cell RCC: all clear-cell RCC express this protein, whereas no expression can be detected in normal kidney and most other normal tissue. Antibody studies have indicated that this molecule might serve as a therapeutic target. In view of the induction/up-regulation of G250 antigen in RCC, its restricted tissue expression and its possible role in therapy, we set out to molecularly define the G250 antigen, which we identified as a transmembrane protein identical to the tumor-associated antigen MN/CAIX. We determined, by FISH analysis, that the G250/MN/CAIX gene is located on chromosome 9p12-13. In view of the relative immunogenicity of RCC, we investigated whether the G250 antigen can be recognized by TIL derived from RCC patients. The initial characterization of 18 different TIL cultures suggests that anti-G250 reactivity is rare.
Building similarity graph...
Analyzing shared references across papers
Loading...
Karin Grabmaier
Radboud University Nijmegen
Joost L. M. Vissers
Future Diagnostics (Netherlands)
Mirjam C.A. de Weijert
Radboud University Nijmegen
International Journal of Cancer
University of Amsterdam
Radboud University Nijmegen
Ludwig-Maximilians-Universität München
Building similarity graph...
Analyzing shared references across papers
Loading...
Grabmaier et al. (Wed,) studied this question.
synapsesocial.com/papers/6a1c9d566b22da4be8e78be2 — DOI: https://doi.org/10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: